<DOC>
	<DOCNO>NCT01011478</DOCNO>
	<brief_summary>RATIONALE : Rosuvastatin may stop growth tumor cell block enzymes need cell growth . Giving rosuvastatin surgery may kill tumor cell remain surgery . It may also keep polyp form colon cancer come back . It yet know whether rosuvastatin effective placebo treat colon cancer remove surgery . PURPOSE : This randomized phase III trial study rosuvastatin see well work compare placebo treat patient stage I stage II colon cancer remove surgery .</brief_summary>
	<brief_title>Rosuvastatin Treating Patients With Stage I Stage II Colon Cancer That Was Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare effect rosuvastatin v placebo 5-year occurrence adenomatous polyp colon rectum , metachronous colorectal carcinoma , colon cancer recurrence ( APMC+R ) patient resect stage I II colon cancer . Secondary - To determine whether effect rosuvastatin v placebo magnitude patient take aspirin ( regardless dose ) compare patient take aspirin . - To determine whether take aspirin ( regardless dose ) v aspirin decrease occurrence APMC+R , effect , explore relationship dose . - To determine effect rosuvastatin patient familial colorectal cancer . - To determine effect rosuvastatin patient microsatellite unstable tumor ( i.e. , tumor display loss MLH1 MSH2 expression IHC ) . - To determine relationship rosuvastatin therapy feature colorectal adenomas well size number colorectal adenoma . - To compare time APMC+R patient treat rosuvastatin v placebo . - To compare disease-free survival patient treat rosuvastatin v placebo . - To compare overall survival patient treat rosuvastatin v placebo . - To compare rate recurrence colon cancer patient treat rosuvastatin v placebo . - To compare rate second non-colorectal primary cancer patient treat rosuvastatin v placebo . - To determine effect rosuvastatin health-related quality life , global quality life , self-reported symptom . - To compare incidence severity adverse event associate rosuvastatin v placebo . - To assess relevant tumor blood marker may affect metabolism , activity , effect study drug , HMG-CoA reductase , UGT1A6 , P450-2C9 , PTGS2 ( COX-2 ) , possible marker . OUTLINE : This multicenter study . Patients stratify accord family history first-degree relative colorectal cancer ( yes v ) , intend aspirin dose ( none v 81 mg v 325 mg ) , adjuvant therapy colon cancer ( yes v ) . Patients randomize 1 2 treatment arm . - Group 1 : Patients receive oral placebo daily 5 year . - Group 2 : Patients receive oral rosuvastatin daily 5 year . Patients may complete quality-of-life questionnaire baseline 6 , 12 , 36 , 60 , 84 month . Tumor tissue , serum , blood sample may collect periodically biomarker analysis . After completion study treatment , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Inclusion Criteria Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Patients must ability swallow oral medication . Patients must resect adenocarcinoma colon stag American Joint Committee Cancer ( AJCC ) Stage 0 , I , II , III . Patients must surgical resection colon adenocarcinoma curative intent within 1 year prior randomization . ( Laparoscopicallyassisted colectomy permit . ) Patients must complete adjuvant therapy prior randomization . Patients take cardioprotective lowdose aspirin study entry must clinically significant toxicity , determine investigator , preclude continuation aspirin , patient must willing continue aspirin therapy ( 81 mg 325 mg ) throughout study therapy . Colonoscopy requirement within 180 day prior randomization : The patient must either undergone preoperative postoperative document colonoscopy cecum ( small bowel anastomosis ) adequate bowel preparation . All observed polyp must remove . ( Polyps remove colonoscopy surgery perform prior randomization . ) Postoperative serum creatinine perform within 90 day prior randomization must less equal 1.5 x upper limit normal ( ULN ) lab . The following criterion evidence adequate hepatic function base postoperative testing perform within 90 day prior randomization must meet : aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) less equal 3.0 x ULN lab , Total bilirubin less equal 1.5 x ULN lab Exclusion Criteria Tumor distal border locate less 12 cm anal verge . Total colectomy total proctocolectomy . Classic Familial Adenomatous Polyposis , Attenuated Familial Adenomatous Polyposis ( i.e. , 20 adenoma , either synchronous metachronous ) , Hereditary Nonpolyposis Colorectal Cancer ( Lynch Syndrome ) . Malabsorption syndrome , ulcerative colitis , inflammatory bowel disease , resection stomach small bowel , disease significantly affect gastrointestinal function . History document upper GI bleed upper GI ulcerative disease . Statin use within 30 day prior randomization . Hyperlipidemia clinical indication statin therapy prescribe medication . Determination acceptable fast lipid value , within 90 day prior randomization , accordance current dyslipidemia management guideline . Unwillingness discontinue chronic use nonsteroidal antiinflammatory drug ( NSAIDs ) ( cardioprotective lowdose aspirin 81 mg 325 mg ) prior randomization . Anticipated need chronic use NSAIDs ( cardioprotective lowdose aspirin 81 mg 325 mg ) . Inadequately treated hypothyroidism , determine investigator . History myopathy rhabdomyolysis . Hypersensitivity intolerance statin . Chronic drug therapy cyclosporine , coumarin anticoagulant , gemfibrozil , lipidlowering therapy ( fibrates niacin ) , lopinavir/ritonavir , drug ( ketoconazole , spironolactone , cimetidine ) low level activity steroid hormone . Pregnancy lactation time study entry . ( Pregnancy test must perform within 14 day prior randomization accord institutional standard woman childbearing potential . ) Previous malignancy unless patient diseasefree 5 year prior randomization deem physician low risk recurrence . Patients follow cancer eligible diagnose treat within past 5 year : situ cancer basal cell squamous cell carcinoma skin . Other nonmalignant systemic disease would preclude patient receiving rosuvastatin would prevent prolonged followup . Administration investigational agent within 30 day randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>adenomatous polyp</keyword>
	<keyword>stage I colon cancer</keyword>
	<keyword>stage II colon cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
</DOC>